476 related articles for article (PubMed ID: 36109639)
1. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
Mackensen A; Müller F; Mougiakakos D; Böltz S; Wilhelm A; Aigner M; Völkl S; Simon D; Kleyer A; Munoz L; Kretschmann S; Kharboutli S; Gary R; Reimann H; Rösler W; Uderhardt S; Bang H; Herrmann M; Ekici AB; Buettner C; Habenicht KM; Winkler TH; Krönke G; Schett G
Nat Med; 2022 Oct; 28(10):2124-2132. PubMed ID: 36109639
[TBL] [Abstract][Full Text] [Related]
2. Journal Club: Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus.
Boulougoura A; Gendelman H; Surmachevska N; Kyttaris VC
ACR Open Rheumatol; 2023 Nov; 5(11):624-628. PubMed ID: 37766597
[TBL] [Abstract][Full Text] [Related]
3. Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production.
Dingfelder J; Aigner M; Taubmann J; Minopoulou I; Park S; Kaplan CD; Cheng JK; Van Blarcom T; Schett G; Mackensen A; Lutzny-Geier G
Transplant Cell Ther; 2024 Jun; 30(6):582.e1-582.e10. PubMed ID: 38548226
[TBL] [Abstract][Full Text] [Related]
4. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
Müller F; Taubmann J; Bucci L; Wilhelm A; Bergmann C; Völkl S; Aigner M; Rothe T; Minopoulou I; Tur C; Knitza J; Kharboutli S; Kretschmann S; Vasova I; Spoerl S; Reimann H; Munoz L; Gerlach RG; Schäfer S; Grieshaber-Bouyer R; Korganow AS; Farge-Bancel D; Mougiakakos D; Bozec A; Winkler T; Krönke G; Mackensen A; Schett G
N Engl J Med; 2024 Feb; 390(8):687-700. PubMed ID: 38381673
[TBL] [Abstract][Full Text] [Related]
5. CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome.
Pecher AC; Hensen L; Klein R; Schairer R; Lutz K; Atar D; Seitz C; Stanger A; Schneider J; Braun C; Schmidt M; Horger M; Bornemann A; Faul C; Bethge W; Henes J; Lengerke C
JAMA; 2023 Jun; 329(24):2154-2162. PubMed ID: 37367976
[TBL] [Abstract][Full Text] [Related]
6. Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as the Future of Systemic Lupus Erythematosus Treatment.
Kambayana G; Surya Rini S
Curr Rheumatol Rev; 2023 Jun; 19(3):260-269. PubMed ID: 36786138
[TBL] [Abstract][Full Text] [Related]
7. Successful Generation of CD19 Chimeric Antigen Receptor T Cells from Patients with Advanced Systemic Lupus Erythematosus.
Kretschmann S; Völkl S; Reimann H; Krönke G; Schett G; Achenbach S; Lutzny-Geier G; Müller F; Mougiakakos D; Dingfelder J; Flamann C; Hanssens L; Gary R; Mackensen A; Aigner M
Transplant Cell Ther; 2023 Jan; 29(1):27-33. PubMed ID: 36241147
[TBL] [Abstract][Full Text] [Related]
8. Concurrent remission of lymphoma and Sjögren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report.
Sheng L; Zhang Y; Song Q; Jiang X; Cao W; Li L; Yi H; Weng X; Chen S; Wang Z; Wu W; Wang L; Zhao W; Yan Z
Front Immunol; 2023; 14():1298815. PubMed ID: 38173731
[TBL] [Abstract][Full Text] [Related]
9. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
10. CAR T-cell therapy in autoimmune diseases.
Schett G; Mackensen A; Mougiakakos D
Lancet; 2023 Nov; 402(10416):2034-2044. PubMed ID: 37748491
[TBL] [Abstract][Full Text] [Related]
11. CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus.
Taubmann J; Müller F; Yalcin Mutlu M; Völkl S; Aigner M; Bozec A; Mackensen A; Grieshaber-Bouyer R; Schett G
Arthritis Rheumatol; 2024 Apr; 76(4):497-504. PubMed ID: 38114423
[TBL] [Abstract][Full Text] [Related]
12. Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy.
Nunez D; Patel D; Volkov J; Wong S; Vorndran Z; Müller F; Aigner M; Völkl S; Mackensen A; Schett G; Basu S
Mol Ther Methods Clin Dev; 2023 Dec; 31():101104. PubMed ID: 37744005
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus.
Jin X; Xu Q; Pu C; Zhu K; Lu C; Jiang Y; Xiao L; Han Y; Lu L
Cell Mol Immunol; 2021 Aug; 18(8):1896-1903. PubMed ID: 32472023
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
15. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
17. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
[TBL] [Abstract][Full Text] [Related]
18. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial.
Wang W; He S; Zhang W; Zhang H; DeStefano VM; Wada M; Pinz K; Deener G; Shah D; Hagag N; Wang M; Hong M; Zeng R; Lan T; Ma Y; Li F; Liang Y; Guo Z; Zou C; Wang M; Ding L; Ma Y; Yuan Y
Ann Rheum Dis; 2024 May; ():. PubMed ID: 38777376
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Hay KA; Gauthier J; Hirayama AV; Voutsinas JM; Wu Q; Li D; Gooley TA; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Schoch G; Chapuis AG; Till BG; Kiem HP; Ramos JD; Shadman M; Cassaday RD; Acharya UH; Riddell SR; Maloney DG; Turtle CJ
Blood; 2019 Apr; 133(15):1652-1663. PubMed ID: 30728140
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
